Key result
Intravenous nitroglycerine in hypertensive acute heart failure is debated as either a marker of disease severity or a mediator of harm.
Why the study?
Is intravenous nitroglycerine a marker of severity or mediator of harm in patients with hypertensive acute heart failure?
Is intravenous nitroglycerine a marker of severity or mediator of harm in patients with hypertensive acute heart failure?
Answers are grounded in this paper and cite their sources.
This letter to the editor discusses the role of intravenous nitroglycerine in hypertensive acute heart failure, questioning if it is a marker of severity or mediator of harm.
To the EditorWe read with great interest the study by Miró et al. which examined predictors of adverse outcomes in 2,865 patients presenting with hypertensive acute heart failure (AHF) [1]. The aut...
No takes yet. Share an insight, caveat, or question.
Ömür et al. (2026) studied this question. Intravenous nitroglycerine in hypertensive acute heart failure is debated as either a marker of disease severity or a mediator of harm.
Synapse has enriched 10 related papers. Consider them for comparative context: